RICHLAND, Wash.--(BUSINESS WIRE)--Spurred by broadening medical center acceptance of Cesium-131 as a brachytherapy treatment for prostate cancer, IsoRay Medical, Inc., from fiscal 1st Quarter 2007 to 2nd Quarter 2007, has significantly increased the number of sites that are either revenue producing, in the process of getting licensed for Cesium-131, or are targeted and are in advanced discussions to adopt Cesium-131.
